Precision immunological diagnostics will be a future mainstay in everyday at home and in office testing. Biotome has created novel linear epitopes to assess stomach cancer risk (Helitope®) and SARS-CoV-2 infection (Covitope®). In an effort to provide rapid, at-home testing for stomach cancer and other disease states, Cardea and Biotome have entered into a technology development partnership to usher this product to market. As Biotome’s epitope discovery platform is agnostic, the partnership sets the groundwork to provide tests to consumers in all facets of human health and wellness.
Current Cardea Partnerships
Most Cardea partnerships remain under strict confidentiality, and we are very excited for the day we can announce each of them. We are equally excited about the select few partnerships we can talk about and have highlighted them here.
A video intro to our partnership programs
Publicly announced commercial partners
is actively using Cardea’s CRISPR-Chip Technology to provide insight into key parameters of editing efficiency. Their assays can determine how well a gRNA is binding to a Cas enzyme, and how well a gRNA + Cas complex is binding to its intended target. This insight allows researchers to select only the best guides and Cas enzymes for their editing experiments – saving significant time and resources that would have otherwise been wasted on using ineffective reagents.
The birthplace of the CRISPR-Chip technology, Dr. Kiana Aran’s academic lab provides a great proving ground for application innovation for our Cardean platform. Keck Graduate Institute, a Claremont college, is one of the leading institutes in biomedical research, combining a strong entrepreneurial program with rigorous scientific research creates a nexus of innovation and development not just for technological applications but for the next-generation scientists. Cardea is proud to continue to support our work with Keck Graduate Institute.
Cardea is partnered with Georgia Tech Research Institute (GTRI) through a grant awarded by the Defense Advanced Research Projects Agency (DARPA) to develop a sensing platform to detect airborne SARS-CoV-2 particles as part of DARPA’s SensSARS program.
In addition to SARS-CoV-2 surveillance monitoring, Cardea anticipates that with continued development, this real-time pathogen identification technology could have far-reaching civilian, public health, and defense applications, from agriculture and food supply monitoring to protection against biological or chemical warfare.
A plethora of industries and applications to be served
Cardea's BPU™ Platform is not siloed to any one industry. Anywhere there is life; nature; biology; BPUs can be used to gain valuable insights.